The presentation marks a pivotal update for the Holon-based biotech company, which centers its pipeline on AI-driven target discovery. Dr. Yeku, an expert in gynecologic oncology, is expected to provide insights into the trial's methodology as the company targets a Q1 2027 window for interim median progression-free survival data. COM701 represents a potential first-in-class treatment, currently moving through clinical evaluation to address the immunosuppressive microenvironment of gynecologic cancers.
In section Releases
Compugen to Host Virtual KOL Event on COM701 Ovarian Cancer Trial
Compugen will hold a virtual event on October 5, 2026, to discuss the clinical progress of its anti-PVRIG antibody, COM701. The session features Dr. Oladapo Yeku of Harvard Medical School, who will outline the design of the ongoing MAIA-ovarian adaptive platform trial for relapsed platinum-sensitive ovarian cancer patients.
Beyond the clinical update, Compugen’s research team will demonstrate enhancements to Unigen™, their proprietary computational platform. This technology serves as the backbone for the company's broader immuno-oncology pipeline, which currently includes collaborations with AstraZeneca and Gilead. Following the technical review of the MAIA-ovarian study and platform advancements, management will host a live question-and-answer session.
Comments (0)
No comments yet. Be the first!